Unknown

Dataset Information

Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy.


ABSTRACT:

Importance

Intraocular pressure (IOP) elevations of clinical relevance have been observed after the commonly used 0.05-mL volume for intravitreous injections. However, more recently approved intravitreous agents involve volumes from 0.07 to 0.1 mL. It is not well established whether repeated 0.1-mL intravitreous injections may result in IOP-related complications.

Objective

To investigate the effect of 1 year of repeated 0.1-mL intravitreous injections on IOP outcomes.

Design, setting, and participants

This study was a post hoc analysis of 2 clinical trials investigating the IOP safety of intravitreous lampalizumab on geographic atrophy secondary to age-related macular degeneration. Both trials were conducted between 2014 and 2018 and recruited participants who were 50

SUBMITTER: Bressler NM 

PROVIDER: S-EPMC11190824 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature